Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 5/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149577 | 0.92 | TSHR (0.41) | HTR2AHTR2CHTR2BTBXAS1MAPT | |
| SCHEMBL3955274 | 0.92 | HTR2A (0.38) | HTR2AHTR2CHTR2BTBXAS1MAPT | |
| SCHEMBL24656220 | 0.90 | TSHR (0.44) | HTR2AHTR2CHTR2BTBXAS1MAPT | |
| SCHEMBL24656071 | 0.90 | TSHR (0.44) | HTR2AHTR2CHTR2BTBXAS1MAPT | |
| SCHEMBL28194248 | 0.84 | FAAH (0.39) | HTR2AHTR2CHTR2BFAAHMGLL | |
| SCHEMBL30935670 | 0.84 | CD38 (0.40) | HTR2AHTR2CHTR2BTBXAS1MAPT | |
| SCHEMBL20981048 | 0.83 | ALDH1A1 (0.47) | ELANEMAPTALDH1A1HPGD | |
| SCHEMBL14427881 | 0.81 | NAMPT (0.40) | HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL13096895 | 0.81 | FAAH (0.51) | HTR2AHTR2CHTR2BFAAHMGLL | |
| SCHEMBL1082963 | 0.81 | MAPK1 (0.37) | MAPTALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4504719-A1 | EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325471-A | EGFR inhibitors | 缆图药品公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | GRAUERT MATTHIAS | 2009-04-09 | — | — | US | disclosed |
| EP-2018387-A1 | THIAZOLYLDIHYDROINDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018386-A1 | THIAZOLYLDIHYDROINDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-28 | — | — | EP | disclosed |
| US-20070259855-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| CN-1244532-C | Process for preparing intermediates | AVENTIS CROPSCIENCE SA (FR) | 2006-03-08 | — | — | CN | disclosed |
| EP-1066237-B1 | PROCESSES FOR PREPARING INTERMEDIATES | BAYER CROPSCIENCE SA (FR) | 2005-07-20 | — | — | EP | disclosed |
| CN-1554635-A | Process for preparing intermediates | �ݶ�ũ�ƹɷ�����˾ | 2004-12-15 | — | — | CN | disclosed |
| CN-1163464-C | Process for preparing intermediates | �ݶ�ũ�ƹɷ�����˾ | 2004-08-25 | — | — | CN | disclosed |
| US-6642418-B1 | 1,3-dione compounds from beta keto esters | AVENTIS CROPSCIENCE SA (FR) | 2003-11-04 | — | — | US | disclosed |
| CN-1301246-A | Process for preparing intermediates | ARFANTINOC S A (FR) | 2001-06-27 | — | — | CN | disclosed |
| EP-1066237-A2 | PROCESSES FOR PREPARING INTERMEDIATES | AVENTIS CROPSCIENCE S.A. (FR) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048851-A2 | PROCESSES FOR PREPARING INTERMEDIATES | AVENTIS CROPSCIENCE S.A. (FR) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259855-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | ROR1, RORB, RORA | HTR2A 2182/4885HTR2C 1009/4885HTR2B 1177/4885 |
| US-20090093474-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | HTR2A 2136/4885HTR2C 804/4885HTR2B 1329/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HTR2A 3976/4885HTR2C 3675/4885HTR2B 3899/4885 |
| US-20070238718-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | CYP3A43, CYP3A5, UGT1A3 | HTR2A 2136/4885HTR2C 804/4885HTR2B 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.